Liver stiffness and aspartate aminotransferase levels predict the risk for liver fibrosis progression in hepatitis C virus/HIV-coinfected patients

HIV Medicine

Volumn 16, Issue 4, 2015, Pages 211-218

  Gonzalez, F A ^a   Van den Eynde, E ^b   Perez Hoyos, S ^c   Navarro, J ^d   Curran, A ^d   Burgos, J ^d   Falco V ^d   Ocana I ^d   Ribera, E ^d   Crespo, M ^d  

^a HOSPITAL GARCIA DE ORTA   (Portugal)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Hepatitis C virus; HIV coinfection; Liver fibrosis; Liver stiffness; Transient elastography

Indexed keywords

ASPARTATE AMINOTRANSFERASE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DISEASE COURSE; ELASTOGRAPHY; FEMALE; FOLLOW UP; HEPATITIS C; HEPATOBILIARY PARAMETERS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER FIBROSIS; LIVER STIFFNESS; MALE; MIXED INFECTION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK FACTOR; CHEMICALLY INDUCED; COMPLICATION; EPIDEMIOLOGY; HIV INFECTIONS; LIVER; LIVER CIRRHOSIS; METABOLISM; MIDDLE AGED; PATHOLOGY; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS; PROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; SPAIN;

ADULT; ANTI-HIV AGENTS; ASPARTATE AMINOTRANSFERASES; COINFECTION; DISEASE PROGRESSION; ELASTICITY IMAGING TECHNIQUES; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SPAIN;

EID: 84924718027     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/hiv.12197     Document Type: Article

References (46)

1. Grint D, Peters L, Schwarze-Zander C etal. Temporal changes and regional differences in treatment uptake of hepatitis C therapy in EuroSIDA. HIV Med 2013; 14: 614-623.
2. Sherman KE, Freeman S, Harrison S, Andron L. Prevalence of antibody to hepatitis C virus in patients infected with the human immunodeficiency virus. J Infect Dis 1991; 163: 414-415.
3. Rumi MG, Colombo M, Gringeri A, Mannucci PM. High prevalence of antibody to hepatitis C virus in multitransfused hemophiliacs with normal transaminase levels. Ann Intern Med 1990; 112: 379-380.
4. Rockstroh JK, Mocroft A, Soriano V etal. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis 2005; 192: 992-1002.
5. Danta M, Brown D, Bhagani S etal. Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours. AIDS 2007; 21: 983-991.
6. González-García J, Navarro San Francisco C, Condes E etal. Trends in HCV infection, liver disease severity, and specific treatment modalities among HIV+ patients: Madrid, Spain. 19th CROI; Seattle 2012. Abstract 746.
7. Graham CS, Baden LR, Yu E etal. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001; 33: 562-569.
8. Sulkowski MS, Mehta SH, Torbenson MS etal. Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults. AIDS 2007; 21: 2209-2216.
9. Rockstroh JK, Bhagani S, Benhamou Y etal. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Med 2008; 9: 82-88.
10. Macias J, Berenguer J, Japon MA etal. Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus. Hepatology 2009; 50: 1056-1063.
11. Lissen E, Clumeck N, Sola R etal. Histological response to pegIFNalpha-2a (40KD) plus ribavirin in HIV-hepatitis C virus co-infection. AIDS 2006; 20: 2175-2181.
12. Berenguer J, Alvarez-Pellicer J, Martin PM etal. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 2009; 50: 407-413.
13. Berenguer J, Rodriguez E, Miralles P etal. Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with HIV and Hepatitis C virus. Clin Infect Dis 2012; 55: 728-736.
14. Laguno M, Cifuentes C, Murillas J etal. Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients. Hepatology 2009; 49: 22-31.
15. Sulkowski MS, Sherman KE, Dieterich DT etal. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Ann Intern Med 2013; 159: 86-96.
16. Sulkowski M, Pol S, Mallolas J etal. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. Lancet Infect Dis 2013; 13: 597-605.
17. EASL recommendations on treatment of hepatitis C. 2014. Available at http://www.easl.eu/_clinical-practice-guideline (accessed 7 July).
18. Afdhal N, Zeuzem S, Kwo P etal. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370: 1889-1898.
19. Mehta SH, Thomas DL, Torbenson M etal. The effect of antiretroviral therapy on liver disease among adults with HIV and hepatitis C coinfection. Hepatology 2005; 41: 123-131.
20. Moodie EE, Pant Pai N, Klein MB. Is antiretroviral therapy causing long-term liver damage? A comparative analysis of HIV-mono-infected and HIV/hepatitis C co-infected cohorts. PLoS ONE 2009; 4: e4517.
21. Verma S, Wang CH, Govindarajan S, Kanel G, Squires K, Bonacini M. Do type and duration of antiretroviral therapy attenuate liver fibrosis in HIV-hepatitis C virus-coinfected patients? Clin Infect Dis 2006; 42: 262-270.
22. Marine-Barjoan E, Saint-Paul MC, Pradier C etal. Impact of antiretroviral treatment on progression of hepatic fibrosis in HIV/hepatitis C virus co-infected patients. AIDS 2004; 18: 2163-2170.
23. Brau N, Salvatore M, Rios-Bedoya CF etal. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol 2006; 44: 47-55.
24. European Association for Study of L. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2014; 60: 392-420.
25. Loko MA, Bani-Sadr F, Valantin MA etal. Antiretroviral therapy and sustained virological response to HCV therapy are associated with slower liver fibrosis progression in HIV-HCV-coinfected patients: study from the ANRS CO 13 HEPAVIH cohort. Antivir Ther 2012; 17: 1335-1343.
26. Vergara S, Macias J, Rivero A etal. The use of transient elastometry for assessing liver fibrosis in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis 2007; 45: 969-974.
27. de Ledinghen V, Douvin C, Kettaneh A etal. Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr 2006; 41: 175-179.
28. Sandrin L, Fourquet B, Hasquenoph JM etal. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003; 29: 1705-1713.
29. Castera L, Vergniol J, Foucher J etal. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128: 343-350.
30. Ziol M, Handra-Luca A, Kettaneh A etal. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005; 41: 48-54.
31. Kirk GD, Astemborski J, Mehta SH etal. Assessment of liver fibrosis by transient elastography in persons with hepatitis C virus infection or HIV-hepatitis C virus coinfection. Clin Infect Dis 2009; 48: 963-972.
32. Diggle P, Heagerty P, Kung-Yee Liang SZ. Analysis of Longitudinal Data, 2nd edn. Oxford; New York, Oxford University Press, 2002.
33. Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. Hepatology 2002; 36 (5 Suppl 1): S47-S56.
34. Limketkai BN, Mehta SH, Sutcliffe CG etal. Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV. JAMA 2012; 308: 370-378.
35. Dufour DR, Lott JA, Nolte FS, Gretch DR, Koff RS, Seeff LB. Diagnosis and monitoring of hepatic injury. II. Recommendations for use of laboratory tests in screening, diagnosis, and monitoring. Clin Chem 2000; 46: 2050-2068.
36. Kamimoto Y, Horiuchi S, Tanase S, Morino Y. Plasma clearance of intravenously injected aspartate aminotransferase isozymes: evidence for preferential uptake by sinusoidal liver cells. Hepatology 1985; 5: 367-375.
37. Benhamou Y, Bochet M, Di Martino V etal. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999; 30: 1054-1058.
38. Kirk GD, Mehta SH, Astemborski J etal. HIV, age, and the severity of hepatitis C virus-related liver disease: a cohort study. Ann Intern Med 2013; 158: 658-666.
39. Ryan P, Berenguer J, Michelaud D etal. Insulin resistance is associated with advanced liver fibrosis and high body mass index in HIV/HCV-coinfected patients. J Acquir Immune Defic Syndr 2009; 50: 109-110.
40. Sterling RK, Contos MJ, Smith PG etal. Steatohepatitis: risk factors and impact on disease severity in human immunodeficiency virus/hepatitis C virus coinfection. Hepatology 2008; 47: 1118-1127.
41. Pineda JA, Macias J. Progression of liver fibrosis in patients coinfected with hepatitis C virus and human immunodeficiency virus undergoing antiretroviral therapy. J Antimicrob Chemother 2005; 55: 417-419.
42. Macias J, Castellano V, Merchante N etal. Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine. AIDS 2004; 18: 767-774.
43. Lin W, Weinberg EM, Tai AW etal. HIV increases HCV replication in a TGF-beta1-dependent manner. Gastroenterology 2008; 134: 803-811.
44. Shafran SD. Early initiation of antiretroviral therapy: the current best way to reduce liver-related deaths in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr 2007; 44: 551-556.
45. de Ledinghen V, Vergniol J, Foucher J, Merrouche W, le Bail B. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography. Liver Int 2012; 32: 911-918.
46. Castera L, Foucher J, Bernard PH etal. Pitfalls of liver stiffness measurement: a 5-year prospective study of 13, 369 examinations. Hepatology 2010; 51: 828-835.